

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	6	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	9	JUL 27	CA/CAPLUS enhanced with new citing references
NEWS	10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS	11	JUL 21	USGENE adds bibliographic and sequence information
NEWS	12	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS	13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS	14	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	15	AUG 17	CAS REGISTRY, the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone
NEWS	16	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	17	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	18	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:24:36 ON 27 AUG 2009

=> file medline, biosis, uspatful, dgene, embase, wpids
COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
FULL ESTIMATED COST 4.84 4.84

FILE 'MEDLINE' ENTERED AT 11:37:35 ON 27 AUG 2009

FILE 'BIOSIS' ENTERED AT 11:37:35 ON 27 AUG 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 11:37:35 ON 27 AUG 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 11:37:35 ON 27 AUG 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 11:37:35 ON 27 AUG 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:37:35 ON 27 AUG 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

=> s graft versus host disease
4 FILES SEARCHED...

L1 207271 GRAFT VERSUS HOST DISEASE

=> s l1 and (iimmunosuppressive drug and copolymer-1)
4 FILES SEARCHED...

L2 0 L1 AND (IIMUNOSUPPRESSIVE DRUG AND COPOLYMER-1)

=> s l1 and (copolymer-1)
4 FILES SEARCHED...

L3 179 L1 AND (COPOLYMER-1)

=> s l3 and (rapamycin or cyclosporine A)
4 FILES SEARCHED...

L4 71 L3 AND (RAPAMYCIN OR CYCLOSPORINE A)

=> d l4 ti abs ibib 1-15

L4 ANSWER 1 OF 71 USPATFULL on STN

TI Dual variable domain immunoglobulin and uses thereof

AB The present invention relates to engineered multivalent and
 multispecific binding proteins, methods of making, and specifically to
 their uses in the prevention and/or treatment of acute and chronic
 inflammatory and other diseases.

ACCESSION NUMBER: 2009:240622 USPATFULL
TITLE: Dual variable domain immunoglobulin and uses thereof
INVENTOR(S): Wu, Chengbin, Shrewsbury, MA, UNITED STATES
 Ghayur, Tariq, Holliston, MA, UNITED STATES
 Dixon, Richard W., Jefferson, MA, UNITED STATES
 Salfeld, Jochen G., North Grafton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090215992	A1	20090827

APPLICATION INFO.: US 2007-890215 A1 20070803 (11)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2006-507050, filed
on 18 Aug 2006, PENDING

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2005-709911P	20050819 (60)
	US 2005-732892P	20051102 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	YANKWICH & ASSOCIATES, P.C., (AND ABBOTT BIORESEARCH CENTER), 201 BROADWAY, CAMBRIDGE, MA, 02139, US	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	11750	

L4 ANSWER 2 OF 71 USPATFULL on STN

TI Method of Treating or Preventing an IL-1 Related Disease or Condition
AB Methods of treating or preventing an IL-1 related disease or condition
in a mammal comprising administering an effective amount of an
IL-1 β binding antibody or IL-1 β binding fragment thereof. An
IL-1 β binding antibody or IL-1 β binding fragment thereof is
provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID
NO: 11, and related nucleic acids, vectors, cells, and compositions, and
a method of preparing an affinity matured IL-1 β binding
polypeptide. IL-1 β binding antibodies or IL-1 β binding
fragments thereof are provided which have desirable affinity and
potency.

ACCESSION NUMBER: 2009:239204 USPATFULL
TITLE: Method of Treating or Preventing an IL-1 Related
Disease or Condition
INVENTOR(S): Masat, Linda, Walnut Creek, CA, UNITED STATES
Haak-Frendscho, Mary, Newark, CA, UNITED STATES
Chen, Gang, San Diego, CA, UNITED STATES
Horwitz, Arnold, San Leandro, CA, UNITED STATES
Roell, Marina, Concord, CA, UNITED STATES
PATENT ASSIGNEE(S): XOMA TECHNOLOGY LTD., Berkeley, CA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20090214568	A1	20090827
APPLICATION INFO.:	US 2009-464006	A1	20090511 (12)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-472813, filed on 21 Jun 2006, Pat. No. US 7531166		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2005-692830P	20050621 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	K&L Gates LLP, P. O. BOX 1135, CHICAGO, IL, 60690-1135, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	4543	

L4 ANSWER 3 OF 71 USPATFULL on STN

TI Method of Treating or Preventing an IL-1 Related Disease or Condition
AB Methods of treating or preventing an IL-1 related disease or condition
in a mammal comprising administering an effective amount of an
IL-1 β binding antibody or IL-1 β binding fragment thereof. An
IL-1 β binding antibody or IL-1 β binding fragment thereof is
provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID
NO: 11, and related nucleic acids, vectors, cells, and compositions, and
a method of preparing an affinity matured IL-1 β binding
polypeptide. IL-1 β binding antibodies or IL-1 β binding
fragments thereof are provided which have desirable affinity and
potency.

ACCESSION NUMBER: 2009:239181 USPATFULL
TITLE: Method of Treating or Preventing an IL-1 Related
Disease or Condition
INVENTOR(S): Masat, Linda, Walnut Creek, CA, UNITED STATES
Haak-Frendscho, Mary, Newark, CA, UNITED STATES
Chen, Gang, San Diego, CA, UNITED STATES
Horwitz, Arnold, San Leandro, CA, UNITED STATES
Roell, Marina, Concord, CA, UNITED STATES
PATENT ASSIGNEE(S): XOMA TECHNOLOGY LTD., Berkeley, CA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090214545	A1	20090827
APPLICATION INFO.:	US 2009-464061	A1	20090511 (12)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-472813, filed on 21 Jun 2006, Pat. No. US 7531166		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-692830P	20050621 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	K&L Gates LLP, P. O. BOX 1135, CHICAGO, IL, 60690-1135, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	4532	

L4 ANSWER 4 OF 71 USPATFULL on STN
TI TREATMENT FOR MULTIPLE SCLEROSIS
AB Methods of treating multiple sclerosis and other disorders are
disclosed.

ACCESSION NUMBER: 2009:225713 USPATFULL
TITLE: TREATMENT FOR MULTIPLE SCLEROSIS
INVENTOR(S): Panzara, Michael, Winchester, MA, UNITED STATES
Sandrock, Alfred, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): BIOGEN IDEC MA INC., Cambridge, MA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090202527	A1	20090813
APPLICATION INFO.:	US 2005-719660	A1	20051118 (11)
	WO 2005-US42052		20051118
			20081120 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-629700P	20041119 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LANDO & ANASTASI, LLP, B2047, ONE MAIN STREET, SUITE 1100, CAMBRIDGE, MA, 02142, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1429	

L4 ANSWER 5 OF 71 USPATFULL on STN

TI Human Antibodies That Bind Human IL-12 And Methods For Producing
AB Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:195461 USPATFULL
TITLE: Human Antibodies That Bind Human IL-12 And Methods For Producing

INVENTOR(S): Salfeld, Jochen, North Grafton, MA, UNITED STATES
Roguska, Michael, Ashland, MA, UNITED STATES
Paskind, Michael, Sterling, MA, UNITED STATES
Banerjee, Subhashis, Hamden, MA, UNITED STATES
Tracey, Daniel, Harvard, MA, UNITED STATES
White, Michael, Framingham, MA, UNITED STATES
Kaymakcalan, Zehra, Westborough, MA, UNITED STATES
Labkovsky, Boris, Marlborough, MA, UNITED STATES
Sakorafas, Paul, Newton Highlands, MA, UNITED STATES
Veldman, Geertruida M., Sudbury, MA, UNITED STATES
Venturini, Amy, Lexington, MA, UNITED STATES
Widom, Angela, Acton, MA, UNITED STATES
Friedrich, Stuart, Cary, NC, UNITED STATES
Warne, Nicholas W., Andover, MA, UNITED STATES
Myles, Angela, Andover, MA, UNITED STATES
Elvin, John Gawain, Cambridge, UNITED KINGDOM
Duncan, Alexander Robert, Cambridge, UNITED KINGDOM
Derbyshire, Elaine Joy, Royston, UNITED KINGDOM
Carmen, Sara, Cambridge, UNITED KINGDOM
Smith, Stephen, Ely, UNITED KINGDOM
Holtet, Thor Las, Royston, UNITED KINGDOM
Du Fou, Sarah Leila, Hitchin, UNITED KINGDOM
PATENT ASSIGNEE(S): Abbott GMBH & Co., KG, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090175857	A1	20090709
APPLICATION INFO.:	US 2008-253103	A1	20081016 (12)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-884830, filed on 1 Jul 2004, Pat. No. US 7504485 Division of Ser. No. US		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 1999-126603P	19990325 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP/ABBOTT, FLOOR 30, SUITE 3000, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	10571	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 6 OF 71 USPATFULL on STN

TI PRODUCTION AND USE OF REGULATORY T CELLS

AB An ex vivo method for generating a population of Treg capable of suppressing rejection of an organ or tissue transplant from a donor animal, comprises culturing CD4.sup.+ T cells from a recipient animal in the presence of IFN- γ plus either donor specific or third-party antigen presenting cells, and harvesting a population of Treg capable of suppressing rejection in the recipient animal. The Treg can be administered, for example intravenously to the recipient, preferably immediately prior to the transplant to suppress transplant rejection. A similar strategy applicable to generating a population of Treg capable of suppressing an autoimmune condition in an animal wherein the animal mounts an immune reaction against an autoantigen, comprises culturing CD4.sup.+ T cells from the animal in the presence of cells presenting the autoantigen and IFN- γ and harvesting a population of autoantigen reactive Treg.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2009:180451 USPATFULL
TITLE:	PRODUCTION AND USE OF REGULATORY T CELLS
INVENTOR(S):	Feng, Gang, Oxfordshire, UNITED KINGDOM Wood, Kathryn Jayne, Oxfordshire, UNITED KINGDOM Bushell, Andrew Richard, Oxfordshire, UNITED KINGDOM
PATENT ASSIGNEE(S):	ISIS INNOVATION LIMITED, Oxfordshire, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20090162334	A1	20090625
APPLICATION INFO.:	US 2007-298323	A1	20070424 (12)
	WO 2007-GB50210		20070424
			20081203 PCT 371 date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	GB 2006-8054	20060424
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BROOKS KUSHMAN P.C., 1000 TOWN CENTER, TWENTY-SECOND FLOOR, SOUTHFIELD, MI, 48075, US	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	820	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 7 OF 71 USPATFULL on STN

TI HUMAN ANTIBODIES THAT BIND HUMAN TNF α

AB Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNF α) are disclosed. These antibodies have high affinity for hTNF α (e.g., K.sub.d=10.sup.-8 M or less), a slow off rate for hTNF α dissociation (e.g., K.sub.off=10.sup.-3 sec.sup.-1 or less) and neutralize hTNF α activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF α and for inhibiting hTNF α activity, e.g., in a human subject suffering from a disorder in which hTNF α activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:172591 USPATFULL

TITLE: HUMAN ANTIBODIES THAT BIND HUMAN TNF α

INVENTOR(S): Salfeld, Jochen G., North Grafton, MA, UNITED STATES
Allen, Deborah J., London, UNITED KINGDOM
Hoogenboom, Hendricus R.J.M, Hasselt, BELGIUM
Kaymakcalan, Zehra, Westborough, MA, UNITED STATES
Labkovsky, Boris, Marlborough, MA, UNITED STATES
Mankovich, John A., Andover, MA, UNITED STATES
McGuinness, Brian T., Cambridge, UNITED KINGDOM
Roberts, Andrew J., Cambridge, UNITED KINGDOM
Sakorafas, Paul, Newton Highlands, MA, UNITED STATES
Schoenhaut, David, Clifton, NJ, UNITED STATES
Vaughan, Tristan J., Cambridge, UNITED KINGDOM
White, Michael, Framingham, MA, UNITED STATES
Wilton, Alison J., Cambridge, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090155205	A1	20090618
APPLICATION INFO.:	US 2009-369451	A1	20090211 (12)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2007-787901, filed on 17 Apr 2007, PENDING Continuation of Ser. No. US 2001-801185, filed on 7 Mar 2001, Pat. No. US 7223394 Continuation of Ser. No. US 1999-125098, filed on 16 Mar 1999, Pat. No. US 6258562 A 371 of International Ser. No. WO 1997-US2219, filed on 10 Feb 1997 Continuation-in-part of Ser. No. US 1996-599226, filed on 9 Feb 1996, Pat. No. US 6090382		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-31476P	19961125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, LLP/ABBOTT, FLOOR 30, SUITE 3000, ONE POST OFFICE SQUARE, BOSTON, MA, 02109-2127, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	2951	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 71 USPATFULL on STN

TI INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING ANTAGONISTS AND
USES THEREFOR

AB The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease). The present invention is further directed to novel therapeutics and therapeutic targets, and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of disorders related to IL-17F signaling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:158710 USPATFULL

TITLE: INTERLEUKIN-17F ANTIBODIES AND OTHER IL-17F SIGNALING
ANTAGONISTS AND USES THEREFOR

INVENTOR(S): CARRENO, BEATRIZ M., CLAYTON, MO, UNITED STATES
COLLINS, MARY, NATICK, MA, UNITED STATES
WRIGHT, JILL F., ASHLAND, MA, UNITED STATES
WOLFMAN, NEIL M., DOVER, MA, UNITED STATES
ARAI, MAYA, BROOKLINE, MA, UNITED STATES
JACOBS, KENNETH, NEWTON, MA, UNITED STATES
LU, ZHIJIAN, BEDFORD, MA, UNITED STATES
GUO, YONGJING, CHESTNUT HILL, MA, UNITED STATES
QIU, YONGCHANG, ACTON, MA, UNITED STATES
PATENT ASSIGNEE(S): WYETH, MADISON, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090142806	A1	20090604
APPLICATION INFO.:	US 2008-196117	A1	20080821 (12)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-353161, filed on 14 Feb 2006, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-653260P	20050214 (60)
	US 2005-667492P	20050401 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WYETH, PATENT LAW GROUP, 5 GIRALDA FARMS, MADISON, NJ, 07940, US	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1-65	
NUMBER OF DRAWINGS:	33 Drawing Page(s)	
LINE COUNT:	5334	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 71 USPATFULL on STN

TI Octahydropentalene compounds as chemokine receptor antagonists

AB The present invention is directed to novel compounds of Formula (I)

##STR1##

pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or stereoisomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, osteoarthritis, multiple sclerosis and asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:131236 USPATFULL
TITLE: Octahydropentalene compounds as chemokine receptor antagonists
INVENTOR(S): George, Dawn M., Charlton, MA, UNITED STATES
Wang, Lu, Northborough, MA, UNITED STATES
Li, Biqin, Northborough, MA, UNITED STATES
Ericsson, Anna M., Shrewsbury, MA, UNITED STATES
Ansell, Graham K., Millbury, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090118298	A1	20090507
APPLICATION INFO.:	US 2008-284758	A1	20080925 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-995148P	20070925 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ABBOTT BIORESEARCH, 100 RESEARCH DRIVE, WORCESTER, MA, 01605-4314, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2719	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 71 USPATFULL on STN
TI Novel therapeutic compounds
AB Disclosed herein are novel compounds of Formula (I),

##STR1##

wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:76212 USPATFULL
TITLE: Novel therapeutic compounds
INVENTOR(S): Breinlinger, Eric C., Charlton, MA, UNITED STATES
Cusack, Kevin P., Holden, MA, UNITED STATES
Hobson, Adrian D., Shrewsbury, MA, UNITED STATES
Li, Bin, Ashland, MA, UNITED STATES
Gordon, Thomas D., Medway, MA, UNITED STATES
Stoffel, Robert H., Harvard, MA, UNITED STATES
Wallace, Grier A., Sterling, MA, UNITED STATES
Grongsaard, Pintipa, Shrewsbury, MA, UNITED STATES

Wang, Lu, Northborough, MA, UNITED STATES
Wang, Lu, Worcester, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090069288	A1	20090312
APPLICATION INFO.:	US 2008-218364	A1	20080715 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-959631P	20070716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ABBOTT BIORESEARCH, 100 RESEARCH DRIVE, WORCESTER, MA, 01605-4314, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6852	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 71 USPATFULL on STN
TI Method of treating or preventing an IL-1 related disease or condition
AB Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1 β binding antibody or IL-1 β binding fragment thereof. An IL-1 β binding antibody or IL-1 β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1 β binding polypeptide is provided. IL-1 β binding antibodies or IL-1 β binding fragments thereof are provided which have desirable affinity and potency.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2009:67176 USPATFULL
TITLE: Method of treating or preventing an IL-1 related disease or condition
INVENTOR(S): Masat, Linda, Oakland, CA, UNITED STATES
Haak-Frendscho, Mary, Newark, CA, UNITED STATES
Chen, Gang, San Diego, CA, UNITED STATES
Horwitz, Arnold, San Leandro, CA, UNITED STATES
Roell, Marina, Concord, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090060923	A1	20090305
APPLICATION INFO.:	US 2008-218997	A1	20080718 (12)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-472813, filed on 21 Jun 2006, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-692830P	20050621 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BELL, BOYD & LLOYD, LLP, P.O. Box 1135, CHICAGO, IL, 60690, US	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	4527	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 71 USPATFULL on STN
TI Method of treating or preventing an IL-1 related disease or condition
AB Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1 β binding antibody or IL-1 β binding fragment thereof. An IL-1 β binding antibody or IL-1 β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO:28, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1 β binding polypeptide is provided. IL-1 β binding antibodies or IL-1 β binding fragments thereof are provided which have desirable affinity and potency.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:67171 USPATFULL
TITLE: Method of treating or preventing an IL-1 related disease or condition
INVENTOR(S): Masat, Linda, Oakland, CA, UNITED STATES
Haak-Frendscho, Mary, Newark, CA, UNITED STATES
Chen, Gang, San Diego, CA, UNITED STATES
Horwitz, Arnold, San Leandro, CA, UNITED STATES
Roell, Marina, Concord, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090060918	A1	20090305
APPLICATION INFO.:	US 2008-218914	A1	20080718 (12)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-472813, filed on 21 Jun 2006, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-692830P	20050621 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BELL, BOYD & LLOYD, LLP, P.O. Box 1135, CHICAGO, IL, 60690, US	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	4613	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 71 USPATFULL on STN
TI Sphingosine-1-phosphate receptor agonist and antagonist compounds
AB The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:32572 USPATFULL
TITLE: Sphingosine-1-phosphate receptor agonist and antagonist compounds
INVENTOR(S): Wallace, Grier A., Sterling, MA, UNITED STATES
Breinlinger, Eric C., Charlton, MA, UNITED STATES
Cusack, Kevin P., Holden, MA, UNITED STATES
Fix-Stenzel, Shannon R., Chicago, IL, UNITED STATES
Gordon, Thomas D., Medway, MA, UNITED STATES

Hobson, Adrian D., Shrewsbury, MA, UNITED STATES
Hayes, Martin E., Lowell, MA, UNITED STATES
Ansell, Graham K., Millbury, MA, UNITED STATES
Grongsaard, Pintipa, Shrewsbury, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090029947	A1	20090129
APPLICATION INFO.:	US 2008-5378	A1	20080311 (12)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2007-4583, filed on 21 Dec 2007, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-876288P	20061221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ABBOTT BIORESEARCH, 100 RESEARCH DRIVE, WORCESTER, MA, 01605-4314, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5882	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 14 OF 71 USPATFULL on STN
TI Methods for Detecting and Treating Autoimmune Disorders
AB The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2009:11597 USPATFULL
TITLE: Methods for Detecting and Treating Autoimmune Disorders
INVENTOR(S): Vandembark, Arthur A., Portland, OR, UNITED STATES
Offner, Halina, Portland, OR, UNITED STATES
Bartholomew, Richard, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090010885	A1	20090108
APPLICATION INFO.:	US 2005-658834	A1	20050729 (11)
	WO 2005-US26915		20050729
			20080820 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-592431P	20040730 (60)
	US 2005-667820P	20050401 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KLARQUIST SPARKMAN, LLP, 121 SW SALMON STREET, SUITE 1600, PORTLAND, OR, 97204, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	3217	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 15 OF 71 USPATFULL on STN
TI ANTIBODY FORMULATIONS
AB Formulations of VLA-4 binding antibody are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:354295 USPATFULL
TITLE: ANTIBODY FORMULATIONS
INVENTOR(S): Maloney, Kevin, Nashua, NH, UNITED STATES
PATENT ASSIGNEE(S): BIOGEN IDEC MA INC., Cambridge, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080311119	A1	20081218
APPLICATION INFO.:	US 2008-139362	A1	20080613 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-944076P	20070614 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LOWRIE, LANDO & ANASTASI, LLP, B2047, ONE MAIN STREET, SUITE 1100, CAMBRIDGE, MA, 02142, US	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2470	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:24:36 ON 27 AUG 2009)

FILE 'MEDLINE, BIOSIS, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT 11:37:35 ON 27 AUG 2009

L1 207271 S GRAFT VERSUS HOST DISEASE
L2 0 S L1 AND (IIMUNOSUPPRESSIVE DRUG AND COPOLYMER-1)
L3 179 S L1 AND (COPOLYMER-1)
L4 71 S L3 AND (RAPAMYCIN OR CYCLOSPORINE A)

=> s l3 and (treating GVHD)
L5 2 L3 AND (TREATING GVHD)

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 2 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGd.
AB Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.
ACCESSION NUMBER: 2006:622796 BIOSIS
DOCUMENT NUMBER: PREV200600641915

TITLE: Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGd.

AUTHOR(S): Anonymous; Aharoni, Rina [Inventor]; Teitelbaum, Dvora [Inventor]; Arnon, Ruth [Inventor]

CORPORATE SOURCE: Rehovot, Israel
ASSIGNEE: Yeda Research and Development CoLtd

PATENT INFORMATION: US 07053043 20060530

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (MAY 30 2006)
CODEN: OGUPE7. ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

ENTRY DATE: Entered STN: 22 Nov 2006
Last Updated on STN: 22 Nov 2006

L5 ANSWER 2 OF 2 USPATFULL on STN

TI Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGd

AB Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:133561 USPATFULL

TITLE: Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGd

INVENTOR(S): Aharoni, Rina, Rehovot, ISRAEL
Teitelbaum, Dvora, Rehovot, ISRAEL
Arnon, Ruth, Rehovot, ISRAEL

PATENT ASSIGNEE(S): Yeda Research and Development Co.Ltd., Rehovot, ISRAEL (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7053043	B1	20060530
	WO 2000027417		20000518
APPLICATION INFO.:	US 1999-831629		19991112 (9)
	WO 1999-US27107		19991112
			20010817 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-145219P	19990723 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Lukton, David	
LEGAL REPRESENTATIVE:	Browdy and Neimark, PLLC	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1430	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:24:36 ON 27 AUG 2009)

FILE 'MEDLINE, BIOSIS, USPATFULL, DGENE, EMBASE, WPIDS' ENTERED AT
11:37:35 ON 27 AUG 2009

L1 207271 S GRAFT VERSUS HOST DISEASE
L2 0 S L1 AND (IIMUNOSUPPRESSIVE DRUG AND COPOLYMER-1)
L3 179 S L1 AND (COPOLYMER-1)
L4 71 S L3 AND (RAPAMYCIN OR CYCLOSPORINE A)
L5 2 S L3 AND (TREATING GVHD)

=> s glatiramer acetate

L6 2846 GLATIRAMER ACETATE

=> s l6 and (GvHD or graft versus host disease)

4 FILES SEARCHED...

L7 173 L6 AND (GVHD OR GRAFT VERSUS HOST DISEASE)

=> s l7 and (immunosuppressive drugs)

L8 28 L7 AND (IMMUNOSUPPRESSIVE DRUGS)

=> d l8 ti abs ibib 1-15

L8 ANSWER 1 OF 28 MEDLINE on STN

TI Combined treatment of glatiramer acetate and low doses
of immunosuppressive drugs is effective in the
prevention of graft rejection.

AB The immunomodulator glatiramer acetate (GA, copolymer
1, Copaxone, GLAT), currently used for the treatment of multiple
sclerosis, is a well-tolerated drug with a high safety profile. We have
previously demonstrated that GA suppresses the immune rejection manifested
in graft versus host disease, as
well as in graft rejection. In an attempt to reduce the dosage and
toxicity of the current immunosuppressive regimens, we have now tested the
ability of GA, combined with low doses of cyclosporin (CyA) or tacrolimus
(FK506), to suppress the rejection of mismatched allografts across major
histocompatibility barriers. We report herewith that such combination
therapy was effective in several animal models: (1) it led to a
significant delay of the vigorous process of skin rejection in mice,
manifested by evidential prolongation in skin graft survival (higher than
that obtained with at least double dose of the immunosuppressive drug
alone). (2) The combined treatment led to efficient inhibition of the
functional deterioration of thyroid grafts in mice, manifested by 2.2- to
20.1-fold increase in iodine absorbance of the transplanted thyroids, as
compared to each drug alone. (3) Combination therapy inhibited
significantly the rejection of vascularized heart transplants in rats.
Thus, cardiac allograft survival following the combined treatment with GA
and low dose of CyA was longer than the survival obtained by fourfold
higher dose of CyA alone. In all transplantation systems, combination
therapy of GA with either CyA or FK506 significantly suppressed graft
rejection and was more effective than treatment with either GA or the
immunosuppressive drug alone, suggesting that such treatment may be
beneficial for human transplantation.

ACCESSION NUMBER: 2004617333 MEDLINE

DOCUMENT NUMBER: PubMed ID: 15589456

TITLE: Combined treatment of glatiramer acetate
and low doses of immunosuppressive drugs
is effective in the prevention of graft rejection.

AUTHOR: Aharoni Rina; Yussim Alexander; Sela Michael; Arnon Ruth

CORPORATE SOURCE: The Department of Immunology, The Weizmann Institute of
Science, Rehovot, Israel.
SOURCE: International immunopharmacology, (2005 Jan) Vol. 5, No. 1,
pp. 23-32.
Journal code: 100965259. ISSN: 1567-5769.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200508
ENTRY DATE: Entered STN: 20 Dec 2004
Last Updated on STN: 9 Aug 2005
Entered Medline: 8 Aug 2005

L8 ANSWER 2 OF 28 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN
TI Combined treatment of glatiramer acetate and low doses
of immunosuppressive drugs is effective in the
prevention of graft rejection.
AB The immunomodulator glatiramer acetate (GA, copolymer
1, Copaxone. GLAT). currently used for the treatment of multiple
sclerosis, is a well-tolerated drug with a high safety profile. We have
previously demonstrated that GA suppresses the immune rejection
manifested in graft versus host
disease, as well as in graft rejection. In an attempt to reduce
the dosage and toxicity of the current immunosuppressive regimens, we have
now tested the ability of GA. combined with low doses of cyclosporin
(CyA) or tacrolimus (FK506), to suppress the rejection of mismatched
allografts across major histocompatibility barriers. We report herewith
that such combination therapy was effective in several animal models: (1)
it led to a significant delay of the vigorous process of skin rejection in
mice, manifested by evidential prolongation in skin graft survival (higher
than that obtained with at least double dose of the immunosuppressive drug
alone). (2) The combined treatment led to efficient inhibition of the
functional deterioration of thyroid grafts in mice, manifested by 2.2- to
20.1-fold increase in iodine absorbance of the transplanted thyroids, as
compared to each drug alone. (3) Combination therapy inhibited
significantly the rejection of vascularized heart transplants in rats.
Thus, cardiac allograft survival following the combined treatment with GA
and low dose of CyA was longer than the survival obtained by fourfold
higher dose of CyA alone. In all transplantation systems. combination
therapy of GA with either CyA or FK506 significantly suppressed graft
rejection and was more effective than treatment with either GA or the
immunosuppressive drug alone, suggesting that such treatment may be
beneficial for human transplantation Copyright 2004 Elsevier B.V. All
rights reserved.

ACCESSION NUMBER: 2005:163671 BIOSIS
DOCUMENT NUMBER: PREV200500163319
TITLE: Combined treatment of glatiramer acetate
and low doses of immunosuppressive drugs
is effective in the prevention of graft rejection.
AUTHOR(S): Aharoni, Rina; Yussim, Alexander; Sela, Michael; Arnon,
Ruth [Reprint Author]
CORPORATE SOURCE: Dept Immunol, Weizmann Inst Sci, IL-76100, Rehovot, Israel
ruth.arnon@weizmann.ac.il
SOURCE: International Immunopharmacology, (January 2005) Vol. 5,
No. 1, pp. 23-32. print.
ISSN: 1567-5769 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 27 Apr 2005

Last Updated on STN: 27 Apr 2005

L8 ANSWER 3 OF 28 USPATFULL on STN
TI Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
AB A method for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells comprises administering to an individual in need thereof an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide, a Copolymer 1-related peptide, and activated T cells which have been activated by Copolymer 1, a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide. The method is particularly useful for stem cell therapy in combination with the agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:212908 USPATFULL
TITLE: Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1
INVENTOR(S): Eisenbach-Schwartz, Michal, Rehovot, ISRAEL
Arnon, Ruth, Rehovot, ISRAEL
Butovsky, Oleg, Beer Sheva, ISRAEL
Ziv, Yaniv, St. Givataim, ISRAEL
Kipnis, Jonathan, Modiin, ISRAEL
Ron, Noga, Katzir, ISRAEL
Eilam, Raya, Jerusalem, ISRAEL
Aharoni, Rina, Rehovot, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090191173	A1	20090730
APPLICATION INFO.:	US 2005-791681	A1	20051129 (11)
	WO 2005-IL1275		20051129
			20080613 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-631163P	20041129 (60)
	US 2005-690498P	20050615 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	COOPER & DUNHAM, LLP, 30 Rockefeller Plaza, 20th Floor, NEW YORK, NY, 10112, US	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1-38	
NUMBER OF DRAWINGS:	51 Drawing Page(s)	
LINE COUNT:	4444	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 28 USPATFULL on STN
TI ANTIBODIES TO IL-17A
AB Engineered antibodies to human IL-17A are provided, as well as uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:195485 USPATFULL
TITLE: ANTIBODIES TO IL-17A
INVENTOR(S): Presta, Leonard G., San Francisco, CA, UNITED STATES
Bowman, Edward P., Redwood City, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 20090175881 A1 20090709
APPLICATION INFO.: US 2007-836318 A1 20070809 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-837197P	20060811 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	4665	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 28 USPATFULL on STN
TI Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris
AB The present invention overcomes limitations of the prior art by providing new compounds and methods for the treatment of conditions, such as neurodegenerative diseases (e.g., multiple sclerosis), psychiatric disorders (e.g., psychosis, bipolar disorder, depression, neuropathic pain), conditions involving CNS-mediated chronic pain, spinal cord injuries, and other diseases or injuries.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2009:67126 USPATFULL
TITLE: Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris
INVENTOR(S): Sporn, Michael B., Tunbridge, VT, UNITED STATES
Liby, Karen T., West Lebanon, NH, UNITED STATES
Gribble, Gordon W., Lebanon, NH, UNITED STATES
Honda, Tadashi, Hanover, NH, UNITED STATES
Letterio, John, Concord, OH, UNITED STATES
PATENT ASSIGNEE(S): Reata Pharmaceuticals, Inc., Irving, TX, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20090060873	A1	20090305
APPLICATION INFO.:	US 2008-151425	A1	20080505 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-916273P	20070504 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701, US	
NUMBER OF CLAIMS:	137	
EXEMPLARY CLAIM:	1-25	
NUMBER OF DRAWINGS:	34 Drawing Page(s)	
LINE COUNT:	3931	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 28 USPATFULL on STN
TI Methods of treating lupus using CD4 antibodies
AB Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The

methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody that results in an improvement in renal function and/or a reduction in proteinuria or active urinary sediment are also provided. Methods of treating lupus or decreasing autoantibody titer by administration of a non-depleting CD4 antibody are also provided. Methods of treating multiple sclerosis by administration of a non-depleting CD4 antibody, optionally in combination with another compound used clinically or experimentally to treat MS, are described. Methods of treating transplant recipients and subjects with rheumatoid arthritis, asthma, psoriasis, Crohn's disease, ulcerative colitis, and Sjogren's syndrome are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:319023 USPATFULL
 TITLE: Methods of treating lupus using CD4 antibodies
 INVENTOR(S): Irving, Bryan, San Francisco, CA, UNITED STATES
 PATENT ASSIGNEE(S): GENENTECH, INC., South San Francisco, CA, UNITED STATES
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080279848	A1	20081113
APPLICATION INFO.:	US 2008-7934	A1	20080320 (12)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2007-724595, filed on 14 Mar 2007, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-919505P	20070321 (60)
	US 2006-783535P	20060316 (60)
	US 2006-873881P	20061207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	42 Drawing Page(s)	
LINE COUNT:	4796	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 28 USPATFULL on STN
 TI Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
 AB The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:182895 USPATFULL
 TITLE: Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
 INVENTOR(S): Larsen, Christian P., Atlanta, GA, UNITED STATES
 Pearson, Thomas C., Atlanta, GA, UNITED STATES
 Adams, Andrew B., Atlanta, GA, UNITED STATES
 Peach, Robert J., San Diego, CA, UNITED STATES
 Linsley, Peter S., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S):

Naemura, Joseph Roy, Bellevue, WA, UNITED STATES
Bajorath, Jorgen, Bonn, GERMANY, FEDERAL REPUBLIC OF
Bristol-Myers Squibb Company, Princeton, NJ, UNITED
STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080160022	A1	20080703
APPLICATION INFO.:	US 2007-978701	A1	20071029 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-155514, filed on 23 May 2002, Pat. No. US 7304033		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293402P	20010523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MANDEL & ADRIANO, 572 EAST GREEN STREET, SUITE 230, PASADENA, CA, 91101, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	2981	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 8 OF 28 USPATFULL on STN

TI Methods for designing and synthesizing directed sequence polymer
compositions via the directed expansion of epitope permeability

AB The instant invention comprises a process for the solid phase synthesis
of directed epitope peptide mixtures useful in the modulation of
unwanted immune responses, such process defined by a set of rules
regarding the identity and the frequency of occurrence of amino acids
that substitute a base or native amino acid of a known epitope. The
resulting composition is a mixture of related peptides for therapeutic
use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:167846 USPATFULL

TITLE: Methods for designing and synthesizing directed
sequence polymer compositions via the directed
expansion of epitope permeability

INVENTOR(S): Bonnin, Dustan, Belmont, MA, UNITED STATES

PATENT ASSIGNEE(S): Peptimmune, Inc., Cambridge, MA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080146504	A1	20080619
APPLICATION INFO.:	US 2007-787229	A1	20070413 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-792085P	20060413 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROPES & GRAY LLP, PATENT DOCKETING 39/41, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	4787	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 28 USPATFULL on STN

TI Methods for the Treatment of Autoimmune Disorders Using
Immunosuppressive Monoclonal Antibodies with Reduced Toxicity
AB The present invention provides methods of treating, preventing, slowing
the progression of, or ameliorating the symptoms of T cell mediated
immunological diseases, particularly autoimmune diseases (e.g.,
autoimmune diabetes (i.e. type 1 diabetes or insulin-dependent diabetes
mellitus (IDDM)) and multiple sclerosis) through the use of anti-human
CD3 antibodies. The antibodies of the invention of the invention are
preferably used in low dose dosing regimens, chronic dosing regimens or
regimens that involve redosing after a certain period of time. The
methods of the invention provide for administration of antibodies that
specifically bind the epsilon subunit within the human CD3 complex. Such
antibodies modulate the T cell receptor/alloantigen interaction and,
thus, regulate the T cell mediated cytotoxicity associated with
autoimmune disorders. Additionally, the methods of the invention provide
for use of anti-human CD3 antibodies modified such that they exhibit
reduced or eliminated effector function and T cell activation as
compared to non-modified anti-human CD3 antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:110220 USPATFULL
TITLE: Methods for the Treatment of Autoimmune Disorders Using
Immunosuppressive Monoclonal Antibodies with Reduced
Toxicity
INVENTOR(S): Koenig, Scott, Rockville, MD, UNITED STATES
Wilder, Ronald L., Rockville, MD, UNITED STATES
Bonvini, Ezio, Rockville, MD, UNITED STATES
Johnson, Leslie S., Darnestown, MD, UNITED STATES
Pillemer, Stanley R., North Potomac, MD, UNITED STATES
PATENT ASSIGNEE(S): MacroGenics, Inc., Rockville, MD, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080095766	A1	20080424
APPLICATION INFO.:	US 2007-763434	A1	20070614 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-813903P	20060614 (60)
	US 2006-871361P	20061221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KING & SPALDING, 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036-4003, US	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	6647	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 28 USPATFULL on STN

TI WSX-1/p28 as a target for anti-inflammatory responses
AB Compositions and methods relating to WSX-1 and p28 (IL-30) are provided.
In particular, methods of treating inflammatory conditions in mammalian
subjects using various WSX-1, p28, EBI3, and gp130 polypeptides and
complexes or moieties that bind to or modulate activity of such
complexes are described. Isolated or recombinant complexes including

soluble WSX-1 or gp130 polypeptides, isolated or recombinant WSX-1 fusion proteins, and isolated or recombinant p28 fusion proteins are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:43603 USPATFULL
TITLE: WSX-1/P28 as a target for anti-inflammatory responses
INVENTOR(S): Hunter, Christopher A., Swarthmore, PA, UNITED STATES
Stumhofer, Jason Scott, Plymouth Meeting, PA, UNITED STATES
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania,
Philadelphia, PA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080038223	A1	20080214
APPLICATION INFO.:	US 2007-880121	A1	20070718 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-832213P	20060719 (60)
	US 2006-837450P	20060811 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	4628	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 28 USPATFULL on STN

TI Methods of treating lupus using CD4 antibodies

AB Methods of treating lupus, including systemic lupus erythematosus, cutaneous lupus erythmetosus, and lupus nephritis, are provided. The methods involve administration of a combination of a non-depleting CD4 antibody and another compound used clinically or experimentally to treat lupus. Methods of treating lupus nephritis by administration of a non-depleting CD4 antibody that results in an improvement in renal function and/or a reduction in proteinuria or active urinary sediment are also provided. Methods of treating multiple sclerosis by administration of a non-depleting CD4 antibody, optionally in combination with another compound used clinically or experimentally to treat MS, are described. Methods of treating transplant recipients and subjects with rheumatoid arthritis, asthma, psoriasis, Crohn's disease, ulcerative colitis, and Sjogren's syndrome are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:249428 USPATFULL
TITLE: Methods of treating lupus using CD4 antibodies
INVENTOR(S): Irving, Bryan, San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070218062	A1	20070920
APPLICATION INFO.:	US 2007-724595	A1	20070314 (11)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2006-783535P 20060316 (60)
 US 2006-873881P 20061207 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX
 458, ALAMEDA, CA, 94501, US
 NUMBER OF CLAIMS: 40
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 41 Drawing Page(s)
 LINE COUNT: 4697
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 28 USPATFULL on STN
 TI Combined treatments comprising synthetic peptide copolymers for
 preventing graft rejection
 AB Compositions and methods for the treatment of graft rejection associated
 with transplantation of tissues and organs include combined treatment
 involving at least one agent selected from Copolymer 1, a copolymer
 1-related heteropolymer or an ordered peptide in combination with at
 least one additional known immunosuppressive agent. Compositions and
 methods for the treatment of graft rejection using ordered peptides or
 ordered copolymer 1-related heteropolymers as monotherapy are also
 provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2006:322345 USPATFULL
 TITLE: Combined treatments comprising synthetic peptide
 copolymers for preventing graft rejection
 INVENTOR(S): Aharoni, Rina, Rehovot, ISRAEL
 Arnon, Ruth, Rehovot, ISRAEL
 Sela, Michael, Rehovot, ISRAEL
 Yussim, Alex, Tel Aviv, ISRAEL
 PATENT ASSIGNEE(S): YEDA RESEARCH AND DEVELOPMENT CO. LTD., REHOVOT, ISRAEL
 (non-U.S. corporation)
 MOR RESEARCH APPLICATIONS LTD., PETACH TIKVA, ISRAEL
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060276390	A1	20061207
APPLICATION INFO.:	US 2006-566321	A1	20060804 (10)
	WO -IL400695		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-491236P	20030731 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1709	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 13 OF 28 USPATFULL on STN
 TI Cop 1 for treatment of inflammatory bowel diseases
 AB The present invention relates to the use of Copolymer 1 (
 glatiramer acetate), a Copolymer 1-related

polypeptide, or a Copolymer 1-related peptide, for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:308741 USPATFULL
TITLE: Cop 1 for treatment of inflammatory bowel diseases
INVENTOR(S): Aharoni, Rina, Rehovot, ISRAEL
Arnon, Ruth, Rehovot, ISRAEL
Kayhan, Basak, Ankara, TURKEY

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060264354	A1	20061123
APPLICATION INFO.:	US 2004-543764	A1	20040120 (10)
	WO 2004-IL54		20040120
			20060501 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-441136P	20030121 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	COOPER & DUNHAM, LLP, 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	1207	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 28 USPATFULL on STN

TI Methods for pretreating a subject with extracorporeal photopheresis
AB The present invention relates to methods for treating a subject predisposed to an autoimmune disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the autoimmune disease. The present invention also relates to methods for treating a subject predisposed to an atopic disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the atopic disease. The present invention further relates to methods for treating a transplant donor and/or a transplant recipient, or an implant recipient with extracorporeal photopheresis or an effective amount of apoptotic cells prior to the transplant or implantation procedure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:295504 USPATFULL
TITLE: Methods for pretreating a subject with extracorporeal photopheresis
INVENTOR(S): Peritt, David L., Bala Cynwyd, PA, UNITED STATES
Harriman, Gregory, Paoli, PA, UNITED STATES
Foss, Francine M., Woodbridge, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060252674	A1	20061109
APPLICATION INFO.:	US 2005-247111	A1	20051011 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-306859, filed on 29 Nov 2002, PENDING		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-333746P	20011129 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6312	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 15 OF 28 USPATFULL on STN

TI Methods of treating disease with random copolymers

AB The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:228358 USPATFULL

TITLE: Methods of treating disease with random copolymers

INVENTOR(S): Rasmussen, James, Cambridge, MA, UNITED STATES
Zhang, Jianxin, Acton, MA, UNITED STATES
Baldwin, Sam, Westford, MA, UNITED STATES
Zanelli, Eric, Sudbury, MA, UNITED STATES
Yu, Bei, West Roxbury, MA, UNITED STATES
Bonnin, Dustan, Belmont, MA, UNITED STATES
Johnson, Keith, Hudson, MA, UNITED STATES
Krieger, Jeff, Newtonville, MA, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20060194725	A1	20060831
APPLICATION INFO.:	US 2005-283405	A1	20051117 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2005-US16340, filed on 9 May 2005, PENDING Continuation-in-part of Ser. No. WO 2005-US16344, filed on 9 May 2005, PENDING		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2004-569292P	20040507 (60)
	US 2005-663333P	20050318 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624, US	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1-33	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	3452	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=>